Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves Outcomes in Pretreated Patients with Metastatic Cancer By Ogkologos - October 14, 2025 5 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROME study Source RELATED ARTICLESMORE FROM AUTHOR ESMO 2025: A Glimpse Into the Congress Programme, Berlin, Germany, 17-21 October ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer MOST POPULAR Inavolisib Plus Palbociclib–Fulvestrant Prolongs PFS in Patients with PIK3CA-mutated, HR-positive, HER2-negative... November 28, 2024 For Women Returning from Breast Cancer Treatment, Work Often Changes Involuntarily April 28, 2021 FDA Approves Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma July 12, 2022 Can Immunotherapy Succeed in Glioblastoma? May 24, 2018 Load more HOT NEWS Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and... Taking Time for the Everyday Things in 2024 New on NCI’s Websites for November 2024 EMA Recommends Extension of Therapeutic Indications for Tislelizumab
